Vaccines for bovine tuberculosis: current views and future prospects

Area of Science:

• Veterinary Medicine
• Infectious Diseases
• Immunology

Background:

• Bovine tuberculosis (TB), caused by Mycobacterium bovis, is a growing concern in cattle populations worldwide, including the UK, New Zealand, and USA.
• Mycobacterium bovis infections contribute to a significant proportion of human tuberculosis cases globally, presenting a dual health and economic challenge.
• Current control strategies, like skin testing and slaughter, are insufficient to curb rising bovine TB incidence in the UK, necessitating improved vaccination approaches.

Purpose of the Study:

• To address the limitations of current bovine tuberculosis control measures by exploring enhanced vaccination strategies.
• To investigate potential improvements for the Bacillus Calmette-Guérin (BCG) vaccine to achieve higher efficacy in cattle.
• To identify vaccination strategies applicable to both bovine and human tuberculosis control.

Main Methods:

• Review and discussion of existing literature on BCG vaccine efficacy and potential modifications.
• Exploration of novel strategies to enhance BCG vaccine performance in cattle.
• Analysis of the applicability of improved BCG strategies for human tuberculosis.

Main Results:

• The current BCG vaccine demonstrates variable efficacy in both cattle and humans.
• Several potential strategies exist to improve BCG vaccine efficacy against bovine tuberculosis.
• These strategies hold promise for enhancing protection against tuberculosis in both animal and human populations.

Conclusions:

• Improving the efficacy of the BCG vaccine is crucial for effective control of bovine tuberculosis.
• Enhanced BCG vaccination strategies could significantly reduce the incidence of bovine TB and its zoonotic transmission.
• The findings offer a pathway towards more effective global tuberculosis control in both cattle and humans.